Arthur M. Cohen & Associates’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.28M | Sell |
6,628
-632
| -9% | -$343K | 0.58% | 28 |
|
|
2025
Q4 | $4.21M | Buy |
7,260
+66
| +0.9% | +$37.3K | 0.69% | 26 |
|
|
2025
Q3 | $3.49M | Sell |
7,194
-1,095
| -13% | -$510K | 0.59% | 28 |
|
|
2025
Q2 | $3.36M | Sell |
8,289
-166
| -2% | -$69.4K | 0.59% | 29 |
|
|
2025
Q1 | $4.21M | Sell |
8,455
-629
| -7% | -$341K | 0.81% | 26 |
|
|
2024
Q4 | $4.73M | Sell |
9,084
-1,244
| -12% | -$684K | 0.84% | 25 |
|
|
2024
Q3 | $6.33M | Sell |
10,328
-187
| -2% | -$111K | 1.14% | 18 |
|
|
2024
Q2 | $5.81M | Buy |
10,515
+481
| +5% | +$276K | 1.07% | 19 |
|
|
2024
Q1 | $5.83M | Sell |
10,034
-36
| -0.4% | -$20.2K | 1.23% | 18 |
|
|
2023
Q4 | $5.35M | Buy |
10,070
+99
| +1% | +$47.9K | 1.26% | 18 |
|
|
2023
Q3 | $5.04M | Sell |
9,971
-3,114,080
| -100% | -$1.66B | 1.29% | 16 |
|
|
2023
Q2 | $5.21M | Buy |
3,124,051
+3,113,975
| +30,905% | +$1.68B | 1.29% | 18 |
|
|
2023
Q1 | $5.8M | Sell |
10,076
-1,103
| -10% | -$622K | 1.56% | 17 |
|
|
2022
Q4 | $6.16M | Sell |
11,179
-1
| -0% | -$530 | 1.68% | 15 |
|
|
2022
Q3 | $5.68M | Buy |
11,180
+509
| +5% | +$285K | 1.56% | 16 |
|
|
2022
Q2 | $5.8M | Sell |
10,671
-197
| -2% | -$108K | 1.44% | 17 |
|
|
2022
Q1 | $6.42M | Sell |
10,868
-385
| -3% | -$221K | 1.35% | 17 |
|
|
2021
Q4 | $7.51M | Sell |
11,253
-99
| -0.9% | -$61.8K | 1.39% | 18 |
|
|
2021
Q3 | $6.48M | Buy |
11,352
+185
| +2% | +$102K | 1.32% | 17 |
|
|
2021
Q2 | $5.63M | Buy |
11,167
+475
| +4% | +$224K | 1.09% | 21 |
|
|
2021
Q1 | $4.88M | Buy |
10,692
+522
| +5% | +$249K | 1.13% | 18 |
|
|
2020
Q4 | $4.75M | Buy |
10,170
+851
| +9% | +$399K | 1.12% | 18 |
|
|
2020
Q3 | $4.12M | Buy |
9,319
+2,137
| +30% | +$883K | 1.07% | 18 |
|
|
2020
Q2 | $1.25M | Buy |
7,182
+2,657
| +59% | +$891K | 0.38% | 38 |
|
|
2020
Q1 | $1.25M | Buy |
4,525
+45
| +1% | +$14.2K | 0.5% | 32 |
|
|
2019
Q4 | $1.46M | Sell |
4,480
-240
| -5% | -$72.8K | 0.45% | 38 |
|
|
2019
Q3 | $1.38K | Buy |
4,720
+386
| +9% | +$111K | 0.39% | 39 |
|
|
2019
Q2 | $1.28M | Buy |
4,334
+130
| +3% | +$35.8K | 0.44% | 36 |
|
|
2019
Q1 | $1.16M | Buy |
4,204
+462
| +12% | +$115K | 0.41% | 38 |
|
|
2018
Q4 | $837 | Sell |
3,742
-311
| -8% | -$73K | 0.27% | 47 |
|
|
2018
Q3 | $991 | Buy |
+4,053
| New | +$932K | 0.3% | 45 |
|
|
2018
Q2 | – | Sell |
-4,052
| Closed | -$822K | – | 116 |
|
|
2018
Q1 | $822K | Buy |
4,052
+310
| +8% | +$65.1K | 0.31% | 54 |
|
|
2017
Q4 | $837 | Buy |
+3,742
| New | +$717K | 0.23% | 45 |
|
|
2017
Q2 | $635K | Sell |
3,641
-4,609
| -56% | -$774K | 0.25% | 63 |
|
|
2017
Q1 | $857K | Buy |
8,250
+7,713
| +1,436% | +$1.18M | 0.38% | 44 |
|
|
2016
Q4 | $758K | Buy |
+537
| New | +$79.2K | 0.4% | 45 |
|
|
2014
Q3 | $729K | Buy |
+3,860
| New | +$469K | 0.34% | 55 |
|
Other funds holding TMO
VCM
Arthur M. Cohen & Associates's TMO Position: Q1 2026 in Review
Arthur M. Cohen & Associates reduced its Thermo Fisher Scientific (TMO) stake by 8.7% in Q1 2026, selling an estimated $343K and leaving 6,628 shares worth $3.28M. The position accounts for 0.58% of the portfolio, ranked #28.
Arthur M. Cohen & Associates first reported a position in TMO in Q3 2014 and has held it in 37 quarters since. The position peaked at $7.51M in Q4 2021. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Arthur M. Cohen & Associates held 6,628 shares of Thermo Fisher Scientific worth $3.28M as of Q1 2026.
- Arthur M. Cohen & Associates sold 632 Thermo Fisher Scientific shares in Q1 2026, an estimated $343K.
- Thermo Fisher Scientific made up 0.58% of Arthur M. Cohen & Associates's portfolio in Q1 2026, its #28 holding.
- Arthur M. Cohen & Associates first reported a position in Thermo Fisher Scientific in Q3 2014 and has held it in 37 quarters since.
- Arthur M. Cohen & Associates's Thermo Fisher Scientific position peaked at $7.51M in Q4 2021.
- 2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Arthur M. Cohen & Associates's 13F filing for Q1 2026, filed 8 May 2026.